Julen
Oyarzabal Santamarina
Investigador hasta 2018
Instituto de Salud Carlos III
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (9)
2022
-
CM-352 Efficacy in a Mouse Model of Anticoagulant-Associated Intracranial Hemorrhage
Thrombosis and Haemostasis, Vol. 122, Núm. 8, pp. 1314-1325
2021
-
mRNA-based therapy in a rabbit model of variegate porphyria offers new insights into the pathogenesis of acute attacks
Molecular Therapy - Nucleic Acids, Vol. 25, pp. 207-219
2020
-
2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: In Vivo Evaluation in a Murine Model of Acute Pancreatitis
Journal of medicinal chemistry, Vol. 63, Núm. 17, pp. 9237-9257
-
A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity
Cancer Letters, Vol. 468, pp. 1-13
2019
-
Trimethylamine-N-Oxide (TMAO) Predicts Cardiovascular Mortality in Peripheral Artery Disease
Scientific Reports, Vol. 9, Núm. 1
2018
-
Phenotypic Screening to Discover Novel Chemical Series as Efficient Antihemorrhagic Agents
ACS Medicinal Chemistry Letters, Vol. 9, Núm. 5, pp. 428-433
2017
-
Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors
Frontiers in Pharmacology, Vol. 8, Núm. OCT
-
CM352 reduces brain damage and improves functional recovery in a rat model of intracerebral hemorrhage
Journal of the American Heart Association, Vol. 6, Núm. 6
2016
-
Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels
Journal of Neurochemistry, Vol. 136, Núm. 2, pp. 403-415